Neil H Segal
Overview
Explore the profile of Neil H Segal including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
79
Citations
10140
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Rosen R, Rosen R, Bercz A, Bercz A, Omer D, Omer D, et al.
Dis Colon Rectum
. 2025 Jan;
68(3):300-307.
PMID: 39808079
Background: The watch-and-wait strategy provides an opportunity to pursue nonoperative management in rectal cancer patients with clinical complete response after neoadjuvant therapy. The management of those with near-complete response remains...
2.
Feferman Y, Verheij F, Williams H, Omer D, Pappou E, Wei I, et al.
Ann Surg Oncol
. 2024 Nov;
32(1):184-185.
PMID: 39496902
No abstract available.
3.
Feferman Y, Verheij F, Williams H, Omer D, Pappou E, Wei I, et al.
Ann Surg Oncol
. 2024 Oct;
32(1):128-136.
PMID: 39395915
Introduction: Total mesorectal excision (TME) with intersphincteric resection and handsewn coloanal anastomosis (ISR-CAA) has been shown to be oncologically safe in patients with distal rectal cancer treated with preoperative chemoradiation....
4.
Bektas A, Hakki L, Khan A, Widmar M, Wei I, Pappou E, et al.
JCO Clin Cancer Inform
. 2024 Aug;
8:e2300233.
PMID: 39121392
Purpose: Outcome for patients with nonmetastatic, microsatellite instability (MSI) colon cancer is favorable: however, high-risk cohorts exist. This study was aimed at developing and validating a nomogram model to predict...
5.
Segal N, Tie J, Kopetz S, Ducreux M, Chen E, Dienstmann R, et al.
Br J Cancer
. 2024 Jul;
131(6):1005-1013.
PMID: 39048638
Background: To determine whether the addition of durvalumab (anti-PD-L1) and oleclumab (anti-CD73) to standard-of-care treatment (FOLFOX and bevacizumab) enhances the anti-tumour effect in patients with metastatic colorectal cancer (mCRC). Methods:...
6.
Bullock A, Schlechter B, Fakih M, Tsimberidou A, Grossman J, Gordon M, et al.
Nat Med
. 2024 Jun;
30(9):2558-2567.
PMID: 38871975
Microsatellite stable metastatic colorectal cancer (MSS mCRC; mismatch repair proficient) has previously responded poorly to immune checkpoint blockade. Botensilimab (BOT) is an Fc-enhanced multifunctional anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) antibody...
7.
Segal N, Melero I, Moreno V, Steeghs N, Marabelle A, Rohrberg K, et al.
Nat Commun
. 2024 May;
15(1):4091.
PMID: 38750034
Cibisatamab is a bispecific antibody-based construct targeting carcinoembryonic antigen (CEA) on tumour cells and CD3 epsilon chain as a T-cell engager. Here we evaluated cibisatamab for advanced CEA-positive solid tumours...
8.
Keane F, Yogiaveetil E, Kezlarian B, LaGratta M, Segal N, Abou-Alfa G, et al.
J Gastrointest Oncol
. 2024 Mar;
15(1):500-507.
PMID: 38482249
Background: Oncologists are prescribing checkpoint inhibitors with greater frequency, and an awareness of and ability to recognize immune-related adverse events (irAEs) is a key part of the safe administration of...
9.
Khushalani N, Ott P, Ferris R, Cascone T, Schadendorf D, Le D, et al.
J Immunother Cancer
. 2024 Mar;
12(3).
PMID: 38458639
Background: Resistance to immune checkpoint inhibitors and targeted treatments for cancer is common; thus, novel immunotherapy agents are needed. Urelumab is a monoclonal antibody agonist that binds to CD137 receptors...
10.
Chen I, Jeong J, Romesser P, Hilal L, Cuaron J, Zinovoy M, et al.
Adv Radiat Oncol
. 2024 Feb;
9(2):101382.
PMID: 38370274
Purpose: Colorectal liver metastases (CLMs) represent a radioresistant histology. We aimed to investigate CLM radiation therapy (RT) outcomes and explore the association with treatment parameters. Methods And Materials: This retrospective...